EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure)

CompletedOBSERVATIONAL
Enrollment

873

Participants

Timeline

Start Date

October 1, 2009

Primary Completion Date

May 6, 2020

Study Completion Date

May 6, 2020

Conditions
Pregnancy Related
Trial Locations (17)

1804

Perinatal HIV Research Unit (PHRU), Johannesburg

2001

Wits Reproductive Health Institute (WRHI), Johannesburg

2193

CAPRISA-The Aurum Institute, Johannesburg

4001

CAPRISA eThekwini, Durban

15213

University of Pittsburgh, Pittsburgh

35294

University of Alabama at Birmingham, Birmingham

Unknown

South African MRC HIV CTU Med Research Council; Botha's Hill Clinical Research Site, Durban

South African MRC HIV CTU Med Research Council; Isipingo, Durban

South African MRC HIV CTU Med Research Council; Overport, Durban

South African MRC HIV CTU Med Research Council; R.K. Khan Hospital, Durban

South African MRC HIV CTU Med Research Council; Tongaat, Durban

South African MRC HIV CTU Med Research Council; Umkomaas, Durban

South African MRC HIV CTU Med Research Council; Verulam, Durban

Makerere University-Johns Hopkins University Collaboration, Kampala

UZ-UCSF HIV Prevention Trials Unit, Chitungwiza

UZ-UCSF HIV Prevention Trials Unit, Harare

UZ-UCSF HIV Prevention Trials Unit, Chitungwiza

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Microbicide Trials Network

NETWORK

NCT01209754 - EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) | Biotech Hunter | Biotech Hunter